Search

Pacific Biosciences of California Inc

Gesloten

SectorGezondheidszorg

1.14

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.1400000000000001

Max

1.1400000000000001

Belangrijke statistieken

By Trading Economics

Inkomsten

-45M

-53M

Verkoop

1.8M

39M

EPS

-0.14

Winstmarge

-135.914

Werknemers

485

EBITDA

-37M

-43M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+132.17% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-84M

357M

Vorige openingsprijs

1.14

Vorige sluitingsprijs

1.14

Nieuwssentiment

By Acuity

50%

50%

142 / 340 Rangschikking in Healthcare

Pacific Biosciences of California Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 aug 2026, 19:36 UTC

Correlated Moves
News

Pacific Biosciences reported second-quarter revenue of $39.01 million, missing estimates. Shares are trading lower amid concerns over funding constraints and adoption challenges.

13 aug 2026, 23:06 UTC

Correlated Moves

Pacific Biosciences of California Inc. gained modestly in after-market trading, reflecting broader market trends seen in correlated assets.

12 aug 2026, 23:41 UTC

Pacific Biosciences shares are lower in after-market hours, trading below their 20-day moving average amid easing inflation concerns and broader market conditions.

11 aug 2026, 20:06 UTC

Pacific Biosciences of California is trading higher in a routine session. The stock remains below its 20-day moving average despite today's gains.

10 aug 2026, 23:21 UTC

Pacific Biosciences of California Inc. shares are higher in after-market trading, recovering from earlier losses and gaining since Monday's close.

7 aug 2026, 22:56 UTC

Correlated Moves

Pacific Biosciences shares are lower in after-market trading, retracing from an initial gain as 10X Genomics declines, impacting market sentiment.

6 aug 2026, 23:11 UTC

Pacific Biosciences of California is higher in after-market trading, reflecting positive momentum since Thursday's close, despite being below its 20-day moving average.

5 aug 2026, 23:01 UTC

News

Pacific Biosciences reported lower second-quarter revenue and a wider EPS loss, prompting a reduction in full-year sales guidance. Shares are down in after-market trading.

4 aug 2026, 21:36 UTC

Pacific Biosciences of California remained roughly flat after market hours. Broader market gains were driven by a decline in crude oil prices.

3 aug 2026, 23:36 UTC

Pacific Biosciences of California Inc. shares are roughly flat after-market, remaining near the lower end of their one-month trading range.

31 jul 2026, 19:46 UTC

News
Correlated Moves

Pacific Biosciences of California is trading lower amid a report citing annual sales declines and cash burn concerns impacting its growth outlook.

29 jul 2026, 16:06 UTC

Correlated Moves

Pacific Biosciences of California Inc shares are lower today, reflecting broader market pressure on small-cap equities and a notable decline in correlated assets.

28 jul 2026, 16:12 UTC

Pacific Biosciences is trading higher, rebounding from earlier losses despite broader market caution following declines in the Nikkei 225 Index.

27 jul 2026, 19:06 UTC

Pacific Biosciences is trading higher as the broader market rises, supported by a notable decline in crude oil prices that has eased geopolitical tensions.

24 jul 2026, 22:31 UTC

Pacific Biosciences shares are higher in after-market trading. No specific company news was identified to explain this movement.

22 jul 2026, 18:01 UTC

Correlated Moves

Pacific Biosciences of California shares are lower amid broader market pressures and rising crude oil prices, trading below its 20-day moving average.

21 jul 2026, 13:01 UTC

Pacific Biosciences is rallying in pre-market trading, continuing its upward trend since Monday's close after three sessions of declines. No specific news was identified.

20 jul 2026, 23:01 UTC

Shares of Pacific Biosciences of California are higher in after-market hours, marking a peak cumulative return since Monday's close amid broader market volatility.

Peer Vergelijking

Prijswijziging

Pacific Biosciences of California Inc Prognose

Koersdoel

By TipRanks

132.17% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.67 USD  132.17%

Hoogste 3 USD

Laagste 2 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pacific Biosciences of California Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

142 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat